Reason for the notification
|
|
Initial notification /Amendment
|
Initial notification
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
Name
|
Smith & Nephew plc
|
LEI
|
213800ZTMDN8S67S1H61
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
Description
of the financial instrument, type of instrument
|
Smith
& Nephew plc ordinary shares of USD 0.20
each
|
Identification code
|
ISIN: GB0009223206
|
Nature of the transaction
|
Purchase of ordinary shares through the Company's Dividend
Re-Investment Plan following the 2024 interim dividend payment on 8
November 2024.
|
Date of Transaction
|
2024 - 11 - 08
|
Place of Transaction
|
London Stock Exchange (XLON)
|
Name
(Position)
|
Director / PDMR
|
Price
|
Volume
|
Aggregated information
|
Helen Barraclough
(Group General Counsel and Company Secretary)
|
PDMR
|
9.234
|
421.23522
|
N/A Single Transaction
|
Paul Connolly
(President, Global Operations)
|
PDMR
|
9.234
|
194.91162
|
N/A Single Transaction
|
Phil Cowdy
Chief Corporate Development & Corporate Affairs
Officer
|
PDMR
|
9.234
|
1.9035
|
N/A Single Transaction
|
Mizanu Kebede
(Chief Quality & Regulatory Affairs Officer)
|
PDMR
|
9.234
|
111.64316
|
N/A Single Transaction
|
Deepak Nath
(Chief Executive Officer)
|
Director
|
9.234
|
1924.20518
|
N/A Single Transaction
|
Scott Schaffner
(President, Sports Medicine)
|
PDMR
|
9.234
|
794.95718
|
N/A Single Transaction
|
|
|
|
|
|
Smith & Nephew plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
Date:
November 11, 2024
|
By:
|
/s/
Helen Barraclough
|
|
|
Helen
Barraclough
|
|
|
Company
Secretary
|